CT-132 is a mobile smartphone app that can be used for Migraine prevention.
The CT-132 app “uses biologic and psychologic and behavioral approaches and then adapts to patient responses in order to take a person through a series of steps that, when they execute them, will help prevent migraine over the long term,”
According to the manufacturers, the FDA (US Food and Drug Administration) has approved CT-132 for the use of migraine prevention. (At the time of writing we could not verify this statement.)
The medication’s approval was primarily based on data from 2, double-blind, decentralised randomised trials: the phase 3 ReMMi-D trial and the ReMMiD-C bridging study.
ReMMi-D included more than 500 patients with episodic migraine randomly assigned to receive adjunctive CT-132 or a sham digital therapeutic for 12 weeks. Those receiving the study treatment showed significant reduction in monthly migraine days, meeting its primary outcome, as well as reduced disability, improved quality-of-life outcomes, and high adherence rates. ReMMiD-C showed similar outcomes in a different patient population that included those taking calcitonin gene-related peptide (CGRP) inhibitors.
In its information CT-132 carries no contraindications, and is not intended to be used as a standalone therapy.
CT-132 does not replace or substitute other migraine treatments, and patients who opt for this digital therapeutic should continue their current treatment as directed.
Key Takeaways
- CT-132 is the first FDA-approved digital therapeutic for episodic migraine prevention, intended for use alongside existing treatments.
- Approval was based on two randomized trials showing significant reductions in monthly migraine days and quality-of-life improvements.
0 Comments